证券代码：002424 证券简称：ST 百灵 公告编号：2025-057 贵州百灵企业集团制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 针对公司股票交易异常波动，公司董事会对公司、控股股东及实 际控制人就相关事项进行了核实，现就有关情况说明如下： 1、公司未发现前期披露的信息存在需要更正、补充之处； 2、公司未发现近期公共传媒报道可能或已对公司股票交易价格 产生较大影响的未公开重大信息； 3、公司目前的经营情况及内外部经营环境未发生重大变化； 4、经核查，公司、控股股东和实际控制人不存在关于本公司的 应披露而未披露的重大事项，或处于筹划阶段的重大事项，股票异常 波动期间，公司控股股东、实际控制人未买卖公司股票； 5、公司不存在导致股票交易严重异常波动的未披露事项。 三、是否存在应披露而未披露信息的说明 公司董事会确认，公司目前没有任何根据《深圳证券交易所股票 上市规则》等有关规定应予以披露而未披露的事项或与该事项有关的 筹划、商谈、意向、协议等；董事会也未获悉本公司有根据《深圳证 券交易所股票上市规则》等有关规定应予以 ...

证券代码：002424 证券简称：ST 百灵 公告编号：2025-056 贵州百灵企业集团制药股份有限公司 关于 2025 年第三次临时股东会决议的公告 特别提示： 1、本次股东会未出现否决提案的情形。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、召开时间： 现场会议召开时间：2025年12月30日（星期二）上午十时 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具 体时间为 2025 年 12 月 30 日（现场股东会召开当日）的交易时间， 即 9:15—9:25,9:30—11:30 和 13:00—15:00。通过深圳证券交易所 互联网投票系统进行网络投票的开始时间为 2025 年 12 月 30 日（现 场股东会召开当日）9:15，结束时间为 2025 年 12 月 30 日（现场股 东会结束当日）15:00。 2、召开地点：贵州省安顺市经济技术开发区西航路 212 号贵州 百灵企业集团制药股份有限公司会议室 3、召开方式：现场投票和网络投票相 ...

贵州北斗星律师事务所(以下简称"本所")接受贵州百灵企业集团制 药股份有限公司（以下简称"公司"）委托，指派本所律师郑锡国、张妮 出席了公司于 2025 年 12 月 30 日上午 10：00 在贵州省安顺市经济技术开 发区西航路 212 号贵州百灵企业集团制药股份有限公司会议室召开的公司 2025 年第三次临时股东会（以下简称"本次股东会"）。现根据《中华人 民共和国公司法》、《中华人民共和国证券法》等有关法律、法规及规章 和《贵州百灵企业集团制药股份有限公司章程》（以下简称（"公司章程"）、 《贵州百灵企业集团制药股份有限公司股东大会议事规则》（以下简称"议 本所律师仅就本次股东会的召集和召开程序、出席会议人员的资格、 本次股东会的表决程序、表决结果等事项发表法律意见，不对本次股东会 提案的内容以及提案中所涉事实和数据的真实性、准确性等问题发表意见。 本法律意见书仅供公司为本次股东会之目的使用，不得用于其他任何 目的或用途。本所同意公司可以将本法律意见书作为本次股东会公告材料， 随其他需公告的信息一起向公众披露，本所依法对其中发表的法律意见承 1/10 贵州北斗星律师事务所法律意见书 关于贵州百灵企业集团 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.32% on December 30, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index closed at 13604.07, up 0.49% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Taiji Group (600129) with a closing price of 18.25, up 2.07% [1] - Wanbangde (002082) at 13.89, up 1.98% [1] - Fangsheng Pharmaceutical (603998) at 11.29, up 1.62% [1] - Conversely, *ST Changyao (300391) saw a significant drop of 19.49%, closing at 0.95 [2] Trading Volume and Value - The trading volume and value for key stocks were as follows: - Taiji Group: 87,200 shares traded, with a transaction value of 159 million [1] - Wanbangde: 164,400 shares traded, with a transaction value of 227 million [1] - Fangsheng Pharmaceutical: 48,000 shares traded, with a transaction value of 53.82 million [1] Capital Flow - The Chinese medicine sector experienced a net outflow of 231 million from institutional investors, while retail investors saw a net inflow of 280 million [2] - The capital flow for specific stocks included: - Wanbangde with a net inflow of 48.79 million from institutional investors [3] - Taiji Group with a net inflow of 18.53 million from institutional investors [3] - *ST Changyao had a net outflow of 19.49% [2]

Core Viewpoint - Guizhou Bailing (002424.SZ) has once again been classified as ST (Special Treatment) due to financial misconduct, marking a continuous cycle of financial fraud, penalties, and regulatory scrutiny, with a total of 11.14 billion yuan manipulated over four years [1][4][28]. Financial Manipulation - The company has been involved in financial manipulation by underreporting and overreporting sales expenses to inflate and deflate profits, respectively, with a total adjustment amounting to 11.14 billion yuan over four years [6][28]. - The financial manipulation details include: - 2019: Underreported sales expenses by 350.12 million yuan, inflating profits by 350.12 million yuan (95.73% of that year's profit) - 2020: Underreported sales expenses by 240.81 million yuan, inflating profits by 240.81 million yuan (115.35% of that year's profit) - 2021: Underreported sales expenses by 63.79 million yuan, inflating profits by 63.79 million yuan (45.04% of that year's profit) - 2023: Overreported sales expenses by 459.41 million yuan, deflating profits by 459.41 million yuan (93.17% of that year's profit) [8][29]. Regulatory Actions - The company faced a historic penalty of 25.6 million yuan from the China Securities Regulatory Commission (CSRC), and its internal control reforms were deemed superficial [9]. - The actual controller, Jiang Wei, has been banned from the market for ten years, significantly impacting the company's strategic stability [9]. Legal Issues - Jiang Wei is embroiled in a legal dispute with Huachuang Securities, which is seeking repayment of 1.7 billion yuan due to unpaid debts related to financial support provided in 2019 [10][32]. - The relationship between Jiang Wei and Huachuang Securities has deteriorated from a supportive partnership to a contentious legal battle [11][32]. Financial Performance - Guizhou Bailing has experienced significant financial decline, with a revenue drop of 10.26% in 2024 to 3.825 billion yuan and a negative net profit of 82.44 million yuan [13][34]. - In the first three quarters of 2025, revenue continued to decline by 24.28%, with a net profit of only 21.21 million yuan, indicating ongoing financial challenges [13][34]. R&D and Sales Issues - The company's R&D investment is significantly below industry standards, with R&D expenses as a percentage of revenue at 0.82%, 1.95%, and 1.59% from 2022 to 2024, compared to an average of 4.17% to 4.86% among peers [35]. - Sales expenses are alarmingly high, with a sales expense ratio of 48.46% in 2024, nearly four times that of a competitor [15][35]. Dependency Risks - Guizhou Bailing has a high dependency on a limited number of customers and suppliers, with the top five customers accounting for nearly 40% of revenue and the top five suppliers for over 45% of purchases [37].

Core Viewpoint - Guizhou BaiLing has been repeatedly penalized and labeled as ST (special treatment) due to ongoing financial misconduct, leading to significant management and operational instability [2][3][7]. Financial Misconduct - The company has been involved in a cycle of financial manipulation, with a total of 1.114 billion yuan adjusted over four years, showcasing a pattern of inflating and deflating profits [5][6]. - The China Securities Regulatory Commission (CSRC) issued a record fine of 25.6 million yuan, indicating severe regulatory scrutiny and the ineffectiveness of the company's internal control reforms [7]. Management Issues - The company's actual controller, Jiang Wei, has been banned from the market for ten years, which poses a significant threat to the company's strategic stability [2][7]. - Jiang Wei is embroiled in a legal dispute with Huachuang Securities, which is seeking repayment of 1.7 billion yuan, further complicating the company's financial situation [10][11]. Financial Performance - Guizhou BaiLing's revenue for 2024 was 3.825 billion yuan, a decline of 10.26% year-on-year, with a net loss of 82.44 million yuan, primarily relying on government subsidies to mitigate losses [13]. - In the first three quarters of 2025, revenue continued to decline by 24.28%, with a net profit of only 21.21 million yuan, indicating ongoing financial challenges [13]. Research and Development - The company's R&D expenditure has been significantly lower than industry peers, with R&D expenses as a percentage of revenue at 0.82%, 1.95%, and 1.59% from 2022 to 2024, compared to an average of 4.17% to 4.86% among 69 listed traditional Chinese medicine companies [14]. - The core R&D project, "Tang Ning Tong Luo," has not yet completed its Phase III clinical trials, raising concerns about its future revenue potential [14]. Sales and Market Dependency - Guizhou BaiLing's sales expenses are alarmingly high, with a sales expense ratio of 48.46% in 2024, nearly four times that of Yunnan Baiyao [14]. - The company relies heavily on a concentrated customer and supplier base, with the top five customers accounting for nearly 40% of revenue and the top five suppliers for over 45% of purchases, which could jeopardize its operational stability [16].

Core Viewpoint - The traditional Chinese medicine sector experienced a slight decline of 0.12% on December 26, with ST Bailin leading the drop, while the overall Shanghai Composite Index rose by 0.1% [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 3963.68, up 0.1% [1]. - The Shenzhen Component Index closed at 13603.89, up 0.54% [1]. - The traditional Chinese medicine sector saw a net outflow of 229 million yuan from major funds, while retail investors contributed a net inflow of 195 million yuan [2][3]. Group 2: Individual Stock Performance - Notable gainers included: - Zhongsheng Pharmaceutical (002317) with a closing price of 20.06, up 2.92% [1]. - Wanbangde (002082) closed at 13.70, up 2.09% [1]. - Tongrentang (600085) closed at 32.25, up 1.26% [1]. - Major decliners included: - ST Bailin (002424) closed at 4.59, down 4.97% [2]. - *ST Changyao (300391) closed at 1.47, down 3.92% [2]. - Jinhua Co. (600080) closed at 7.76, down 2.51% [2]. Group 3: Trading Volume and Capital Flow - Zhongsheng Pharmaceutical had a trading volume of 747,200 shares and a transaction value of 149 million yuan [1]. - ST Bailin had a trading volume of 849,300 shares with a transaction value of 391 million yuan [2]. - The capital flow data indicates that major funds had a net inflow in Zhongsheng Pharmaceutical, while other stocks like Tongrentang and Wanbangde saw mixed capital flows [3].

Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. (Guizhou BaiLing, 002424) is under regulatory scrutiny for suspected violations of information disclosure laws, prompting potential compensation claims from affected investors [1][2]. Summary by Relevant Sections Regulatory Attention - The company has attracted regulatory attention due to alleged information disclosure violations, which may impact investor confidence and stock performance [1]. Compensation Eligibility - Investors who suffered losses are eligible to register for compensation if they meet specific trading conditions: - **Time Period One**: Investors who bought Guizhou BaiLing stock between April 30, 2020, and April 30, 2024, and sold or continued to hold the stock after April 30, 2024 [1]. - **Time Period Two**: Investors who bought the stock between April 23, 2022, and April 30, 2024, and sold or continued to hold the stock after April 30, 2024 [1]. Required Documentation for Claims - To participate in the compensation process, investors must prepare the following documents: 1. Original transaction statements for Guizhou BaiLing stock, stamped by the brokerage [2]. 2. Copies of the investor's ID [2]. 3. A securities account inquiry statement issued by the brokerage [2].

受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 根据相关法律意见及信息披露情况，贵州百灵企业集团制药股份有限公司（贵州百灵，002424）因涉嫌 信息披露违法违规，相关事项已引起监管关注。上海百悦律师事务所牛彬律师指出，符合条件的受损投 资者可依法准备索赔。 牛彬律师表示，根据相关情况，暂定符合以下任一时间段交易条件的亏损投资者（包括个人和机构）， 均有权参与索赔登记： 登录新浪财经APP 搜索【信披】查看更多考评等级 索赔暂定条件（时间段一）：（ST百灵维权入口） 凡于2020年4月30日至2024年4月30日期间买入贵州百灵（002424）股票，且在2024年4月30日之后 卖出或继续持有的亏损投资者。 索赔暂定条件（时间段二）： 凡于2022年4月23日至2024年4月30日期间买入贵州百灵（002424）股票，且在2024年4月30日之后卖出 或继续持有的亏损投资者。 索赔材料： 一、买卖贵州百灵（002424）股票的对账单原件 （1） ...

Group 1 - The document lists various companies in Guizhou, focusing on sectors such as agriculture, biotechnology, and pharmaceuticals [1][2][3][4][5][6][7][8][9] - Companies like Guizhou Daziran Technology Co., Ltd. and Guizhou Pharmaceutical Group are highlighted for their roles in health and wellness industries [1][5] - The presence of numerous tea and agricultural product companies indicates a strong emphasis on local agricultural development and eco-friendly practices [2][3][4][6][8] Group 2 - The document includes a variety of companies involved in the production of organic and health-related products, showcasing a trend towards sustainable and health-conscious consumer goods [2][3][5][6] - Companies such as Guizhou Tianzi Guibao Food Co., Ltd. and Guizhou Yuyuan Agricultural Development Co., Ltd. are noted for their contributions to the food and health sectors [5][6][7] - The diversity of companies listed suggests a robust ecosystem for agricultural innovation and development in Guizhou [1][2][3][4][5]